Shire Successfully Completes Tender Offer for ViroPharma - 47 ABC - Delmarva's Choice

Shire Successfully Completes Tender Offer for ViroPharma

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Shire plc

DUBLIN, January 24, 2014 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of ViroPharma (NASDAQ: VPHM). The tender offer expired at midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014), and was not extended.

As of midnight on January 23, 2014, approximately 53,745,956 common shares of ViroPharma (excluding 3,597,087 common shares of ViroPharma guaranteed to be delivered within the next three NASDAQ trading days) had been validly tendered and not withdrawn pursuant to the tender offer, representing approximately 79.5% of the outstanding common shares of ViroPharma.  All shares that were validly tendered and not withdrawn have been accepted for payment.

Later today, Shire expects to complete the merger of ViroPharma with one of its subsidiaries, and, in connection with the merger, all remaining common shares of ViroPharma (excluding shares held by ViroPharma, Shire or certain of their respective subsidiaries or holders who have properly demanded appraisal rights under Delaware law) will be converted into the right to receive $50 per share in cash, the same price that was paid in the tender offer. Following completion of the merger, ViroPharma will become a wholly owned subsidiary of Shire and its shares will cease to be traded on NASDAQ.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

http://www.shire.com

FORWARD - LOOKING STATEMENTS

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

  • Shire's proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement;
  • a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied;
  • ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma's business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; and
  • difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all;

and other risks and uncertainties detailed from time to time in Shire's or ViroPharma's filings with the U.S. Securities and Exchange Commission, including their respective most recent Annual Reports on Form 10-K.

For further information please contact:

Investor Relations, Eric Rojas, erojas@shire.com, +1-781-482-0999

Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894157

Media:

Jessica Mann, jmann@shire.com, +44-1256-894-280

Gwen Fisher, gfisher@shire.com, +1-484-595-9836

©2012 PR Newswire. All Rights Reserved.

  • HealthMore>>

  • FDA to propose e-cigarette regulations

    FDA to propose e-cigarette regulations

    © FDA© FDA
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • 1 in 13 U.S. schoolkids takes psych meds

    1 in 13 U.S. schoolkids takes psych meds

    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>
    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>
Powered by WorldNow
Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and WMDT. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.